2025-10-19 - Analysis Report
Okay, here's an analysis of Tempus AI Inc. (TEM) based on the provided data.

## Report on Tempus AI Inc. (TEM)

Tempus AI Inc. is a technology company focused on precision medicine through data and artificial intelligence.

### 1. Performance vs. S&P 500 (VOO)

**Key Numbers:**

*   **TEM Cumulative Return:** 44.21%
*   **VOO (S&P 500) Cumulative Return:** 26.28%
*   **Absolute Divergence:** 18.3%
*   **Relative Divergence:** 51.2%
*   **Divergence Range:** Min: -40.6, Max: 74.4

**Analysis:**

TEM has significantly outperformed the S&P 500. The cumulative return difference is substantial (18.3%). The Relative Divergence of 51.2% indicates that TEM's outperformance is above the historical median compared to VOO, but not at the extreme upper range.

**Alpha, Beta Analysis**

| Year      | CAGR  | MDD   | Alpha | Beta | Cap(B) |
| :---------- | :---- | :---- | :---- | :--- | :----- |
| 2023-2025 | 44.0% | 77.2% | 19.0% | 0.3  | 15.2   |

**Analysis**

*   **CAGR:** The high CAGR (44%) shows strong growth over the period.
*   **MDD:** The significant MDD (77.2%) shows high volatility and risk.
*   **Alpha:** The positive alpha (19.0%) indicates TEM's ability to generate returns independent of the market.
*   **Beta:** The low beta (0.3) suggests that TEM's price is not very sensitive to market movements, which can be seen as favorable given its high growth potential.
*   **Cap(B):** The market capitalization of 15.2 billion indicates it's a large-cap company.

### 2. Recent Stock Price Movement

**Key Numbers:**

*   **Current Price:** $87.78
*   **Previous Close:** $91.02
*   **Change:** -$3.56
*   **5-Day Moving Average:** $91.01
*   **20-Day Moving Average:** $88.49
*   **60-Day Moving Average:** $77.90

**Analysis:**

The current price is below both the 5-day and 20-day moving averages, suggesting a recent downward trend. The significant change from the previous close (-$3.56) reinforces this. However, the price is still above the 60-day moving average, indicating that the longer-term trend might still be positive.  The sharp drop from the previous close indicates a potential negative event or market correction affecting TEM.

### 3. Technical Indicators

**Key Numbers:**

*   **Market Risk Indicator (MRI):** 0.5 (Low Investment)
*   **RSI:** 59.68
*   **PPO:** -0.97
*   **Hybrid Signal:** Cash 79%, Sell 79.9% of holdings (230 shares - Risky - MRI:0.50)
*   **Recent (20-day) Relative Divergence Change:** -2.6 (Negative - Short-term decline)
*   **Expected Return (%):** NaN

**Analysis:**

*   **MRI:** The MRI suggests "Low Investment," indicating moderate risk.
*   **RSI:** The RSI of 59.68 is nearing overbought territory (above 70).
*   **PPO:** The negative PPO suggests a downward trend in momentum.
*   **Hybrid Signal:** The signal to sell a significant portion (79.9%) of holdings and hold a high cash position (79%) suggests caution due to perceived risk.
*   **Relative Divergence Change:** The negative change in relative divergence confirms a recent short-term decline.
*   **Expected Return:** The "NaN" value for expected return is concerning and may indicate insufficient data or a problem with the calculation.

### 4. Recent News & Significant Events

*   **Collaborations:** Positive news regarding collaborations with Whitehawk Therapeutics to advance oncology research.
*   **Presentations:** Accepted abstracts for presentation at the European Society for Medical Oncology Congress 2025 indicate ongoing research and development.
*   **ARPA-H Program:** Winning a major role in the ARPA-H Adaptive Cancer Program is a significant positive catalyst.
*   **Bull Case:** An article highlighting a "Bull Case Theory" suggests positive sentiment from some analysts.

**Impact:**

The news is predominantly positive, pointing to research advancements, strategic collaborations, and recognition in the industry. The ARPA-H selection is particularly significant.

### 4-2. Analyst Opinions

*   **Consensus:** "Buy" (Mean: 2.15)
*   **Target Price:** Average: $77.55, High: $100.00, Low: $60.00
*   **Recent Rating Changes:** Not provided, so we cannot analyze any changes.

**Analysis:**

The analyst consensus is positive, with a "Buy" rating. The average target price ($77.55) is below the current price ($87.78), suggesting that analysts, on average, believe the stock is currently overvalued. However, the high target price ($100.00) indicates some analysts are very bullish.

### 5. Recent Earnings Analysis

| 날짜       | EPS   | 예상 EPS |
| :--------- | :---- | :------- |
| 2025-08-08 | -0.22 | -0.22988 |
| 2025-05-06 | -0.24 | -0.26003 |
| 2025-02-24 | -0.18 | -0.15    |
| 2024-11-04 | -0.25 | -0.26608 |
| 2024-08-06 | -0.63 | -0.59    |

**Analysis:**

Tempus AI is currently unprofitable, as indicated by the negative EPS values for all reported quarters. In most cases, the actual EPS either met or slightly exceeded expectations, which suggests a degree of predictability or potentially conservative estimates. The largest EPS loss was reported in 2024-08-06.

### 6. Financial Information

| Quarter      | Revenue | Profit Margin |
| :----------- | :------ | :------------ |
| 2025-06-30   | $0.31B  | 61.99%        |
| 2025-03-31   | $0.26B  | 60.69%        |
| 2024-12-31   | $0.20B  | 60.83%        |
| 2024-09-30   | $0.18B  | 58.50%        |
| 2024-06-30   | $0.17B  | 45.50%        |

| Quarter      | Equity    | ROE        |
| :----------- | :-------- | :--------- |
| 2025-06-30   | $0.31B    | -13.84%    |
| 2025-03-31   | $0.33B    | -20.86%    |
| 2024-12-31   | $0.06B    | -23.10%    |
| 2024-09-30   | $0.05B    | -141.16%   |
| 2024-06-30   | $0.10B    | -562.04%   |

**Analysis:**

*   **Revenue:** Revenue has been consistently increasing over the past five quarters, indicating strong growth in Tempus AI's business.
*   **Profit Margin:** The profit margins are very high, consistently above 50%, indicating strong pricing power and efficient operations.
*   **Equity:** The equity is volatile and has seen recent decreases.
*   **ROE:** The negative ROE values reflect the company's unprofitability, consistent with the negative EPS. The extremely negative values in 2024 suggest potential financial instability during that period.

### 7. Overall Assessment

Tempus AI (TEM) is a high-growth company in the precision medicine space. It has significantly outperformed the S&P 500 recently, driven by positive news and a strong revenue growth trajectory. The recent price drop and cautious technical indicators suggest short-term risks. The company is currently unprofitable, but has high profit margins and strong revenue growth. Analyst consensus is positive, although some believe the stock is currently overvalued.

**Recommendation:**

A mixed outlook. The long-term potential seems promising given the company's growth, innovative space, and positive news. However, investors should be aware of the current unprofitability, high volatility, and potential short-term downside risks indicated by technical analysis and analyst target prices. Proceed with caution and consider the high risk/reward profile.
